Bayer has cut KAMs before. SAMs are nothing more than the next version. If Mirena market share does erode severely, KAMs and BDLs, will not be able to drive Kyleena growth sufficiently from their position. Contracting will not be enough to entice providers to switch to Kyleena. A small 120 person sales force is enough to maintain Bayer presence in the GYN market with Kyleena, and build a foundation for the next generation of iud or other products to come. Mirena is 20 years old, and competition for its business is about to get tough.